DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Cydan Raises $34M to Advance New Therapies for Sickle Cell, Other Rare Diseases
Cydan, the company that founded Imara — which developed a sickle cell disease (SCD) treatment candidate, IMR-687 — has raised $34 million in new financing to advance innovative therapies for patients living with SCD and other rare diseases.
Cydan, based in Cambridge, Massachusetts, identifies promising scientific findings and drug candidates and advances them into clinical development. Cydan also establishes independent companies to promote selected therapies through clinical development and regulatory approval. In this round of financing, a new investor, Longitude Capital, joined existing investors New Enterprise Associates (NEA), Pfizer Venture Investments, Alexandria Venture Investments and Lundbeckfond Ventures.


Related Content
-
education & researchNitric Oxide, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators as Candidate Treatments for Sic...Despite being described in the medical l...
-
news & eventsHydroxyurea linked to ‘significant, rapid’ reduction of sperm countSix months of hydroxyurea therapy detrim...
-
videos & visualsInfographic: Understanding Sickle Cell Disease – ASHhttps://www.onescdvoice.com/wp-content/u...
-
education & research8 Tips to Support Students With Sickle Cell DiseaseIn the United States, sickle cell diseas...
-
news & eventsEffort set to help sickle cell patients manage medsVanderbilt University Medical Center is ...
-
news & eventsMount Sinai receives NIH grant to study use of inhaled corticosteroids for sickle cell treatmentThe Departments of Emergency Medicine an...
-
news & eventsGene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.